card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search
3214_Scientific Research Team With Clear Solution in Lab

Vaccines

Assays Contributing to Infectious Disease Therapies

For Vaccines, Antibiotics, and Antivirals

Recent events force the question: What is the best plan to reduce the burden of infectious diseases globally through vaccination and prevention? IQVIA Laboratories Vaccines, has long been at the forefront, aiding in the development of new vaccines and antimicrobial drugs faster and with better methodologies in partnership with premier organizations focused on this task. We continue to commit to prioritizing a swift response to global threats to public health through innovation, collaboration, and action.

 

IQVIA Laboratories Vaccines functions as the reference lab for the Coalition for Epidemic Preparedness Innovations (CEPI) for both SARS-CoV-1, SARS-CoV-2 and MERS. CEPI has established a global network of laboratories transferring viral functional and immunogenicity methods and reagents worldwide for rapid vaccine development.  Their goal is to reduce the threat of future outbreaks and enable equitable access to lifesaving vaccines.

 

Another key partner, Bill & Melinda Gates Foundation, also aims to reduce health inequities through new tools and strategies that reduce infectious diseases, such as HIV, malaria, and pneumonia. In addition, they invest in deep technical expertise and novel platforms for vaccine development to accelerate innovation for better, faster, and affordable vaccines.

 

To ensure the limited resources for infectious disease research are put to best use, the WHO lists diseases that currently pose the greatest public health risk, such as VoC, SARS-CoV-1, MERS and Nipah.

 

Reducing food-borne bacterial infections is an urgent concern across the globe. Targeting specific serotypes of pathogens such as Campylobacter, Cyclospora, Listeria, Salmonella, Shiga toxin-producing Escherichia coli (STEC), Shigella, Vibrio, and Yersinia is one way to better understand outbreaks and prevention. With our experience working with infectious bacteria and our high-throughput functional bacterial assays, we are prepared to support the development of novel vaccines and anti-bacterial drugs. 

Custom Assay Development Services Expedite Your Research

Our longstanding expertise and track record in infectious disease crosses the spectrum of assay development and testing.
Laboratory assistant putting test tubes into the holder

Early Development

We have a highly experienced team and exceptional in vitro bioassay development support for candidate selection. Evaluate immune response with custom, high-performance functional and immunogenicity assays utilizing human immune cells. With efficient, top-tier technology platforms, we will help you ensure functionality and improve your program’s chance of success.

The right animal model can make all the difference. We have developed numerous in vivo models for specific disease states and our experts tailor models to suit your objectives.

Whether you need validated assays for vaccines targeting viral or bacterial agents such as immunogenicity, functional or cellular assays  at IQVIA Laboratories Vaccines, we have the scalable solution.

Agnostic of modality, the nature of the infectious agent drives our assay development and selection utilizing a wide range of solutions. We have the flexibility to adapt assays to study not only the initial disease, but also any variants that may arise.

Global Footprint

IQVIA Laboratories Vaccines is strategically expanding to provide you with more options, expertise, and services.